- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 31/18 - Antivirals for RNA viruses for HIV
Patent holdings for IPC class A61P 31/18
Total number of patents in this class: 4254
10-year publication summary
|
162
|
257
|
301
|
318
|
321
|
274
|
266
|
230
|
208
|
110
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Gilead Sciences, Inc. | 2242 |
287 |
| Duke University | 3186 |
90 |
| ViiV Healthcare UK (no.5) Limited | 89 |
77 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 3014 |
63 |
| ViiV Healthcare Company | 164 |
63 |
| Mondobiotech Laboratories AG | 311 |
56 |
| Merck Sharp & Dohme LLC | 3738 |
54 |
| Bristol-myers Squibb Company | 4764 |
48 |
| Centre National de La Recherche Scientifique | 11077 |
45 |
| The Scripps Research Institute | 1344 |
42 |
| Merck Sharp & Dohme Corp. | 2184 |
41 |
| Shionogi & Co., Ltd. | 884 |
36 |
| The Regents of the University of California | 20842 |
35 |
| The Trustees of the University of Pennsylvania | 4432 |
35 |
| Emory University | 1722 |
31 |
| Janssen Sciences Ireland Unlimited Company | 375 |
31 |
| The Rockefeller University | 582 |
28 |
| Cipla Limited | 479 |
24 |
| Janssen Vaccines & Prevention B.V. | 268 |
24 |
| ViiV Healthcare UK (No. 5) Limited | 49 |
24 |
| Other owners | 3120 |